News
HMDCF
2.900
NaN%
--
HUTCHMED Reports 2026 Interim Results
Barchart · 2d ago
HUTCHMED to Announce 2026 Half-Year Financial Results
Barchart · 06/30 03:30
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
Barchart · 06/24 19:00
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
Barchart · 06/11 19:00
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Barchart · 05/21 19:00
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Barchart · 04/29 05:00
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Barchart · 04/08 19:00
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Barchart · 03/22 19:00
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
Barchart · 03/09 04:30
HUTCHMED Reports 2025 Full Year Results and Business Updates
Barchart · 03/05 05:00
HUTCHMED to Announce 2025 Final Results
Barchart · 02/06 02:30
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Barchart · 01/13 22:00
HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Barchart · 01/06 18:00
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Barchart · 11/26/2025 18:00
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
Barchart · 11/02/2025 18:00
HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Barchart · 10/22/2025 19:00
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Barchart · 10/14/2025 03:30
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
Barchart · 10/12/2025 23:00
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
Barchart · 10/01/2025 19:00
Weekly Report: what happened at HMDCF last week (0908-0912)?
Weekly Report · 09/15/2025 10:13
More
Webull provides a variety of real-time HMDCF stock news. You can receive the latest news about HUTCHMED (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HMDCF
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.